Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries : EU regulators charge Teva over pay-for-delay drug deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 01:36pm CET
A building belonging to Teva Pharmaceutical Industries, the world's biggest generic drugmaker and Israel's largest company, is seen in Jerusalem

BRUSSELS (Reuters) - EU antitrust regulators charged Israeli drugmaker Teva (>> Teva Pharmaceutical Industries Limited) on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

BRUSSELS (Reuters) - EU antitrust regulators charged Israeli drugmaker Teva (>> Teva Pharmaceutical Industries Limited) <TEVA.N> on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

The crackdown by the European Commission follows fines against scores of companies including Denmark's Lundbeck, U.S. giant Johnson & Johnson and France's Servier in recent years over similar deals.

The EU competition enforcer's 2009 inquiry into the sector showed that so-called pay-for-delay deals cost European consumers billions of euros.

Teva, the world's biggest generic drugmaker, reached the deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of Cephalon's patents on the blockbuster drug. This involved cash payments from Cephalon, which Teva later acquired in 2011.

The Commission said the deal may have pushed up prices of the drug, modafinil.

"The patent settlement agreement between Cephalon and Teva may have caused substantial harm to EU patients and health service budgets," the EU competition enforcer said in a statement.

Teva said it strongly disagreed with the Commission's analysis on such deals.

"We do not believe that Cephalon and Teva entered into any anti-competitive behavior," the company said.

Teva, which can ask for a closed-door hearing to defend its case, can be fined up to 10 percent of its global turnover if found guilty of breaching EU antitrust rules. The company made $21.9 billion of revenue in 2016.

It was fined 15.6 million euros ($17.9 million) in 2014 for an illegal deal with Servier.

The Commission in May sent a warning shot to the sector by opening an investigation into alleged excessive pricing by South Africa's Aspen Pharmacare (>> Aspen Pharmacare Holdings Limited) for five cancer medicines.

(Reporting by Foo Yun Chee; Additional reporting by Ari Rabinovitch in Jerusalem; Editing by Philip Blenkinsop and Mark Potter)

By Foo Yun Chee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
02/16BERKSHIRE HATHAWAY : Cramer shocked by Buffett's investment in "second-rate" Tev..
AQ
02/16NOVARTIS : FDA Approves Another New Generic Form of 40mg Copaxone
AQ
02/16Backstory - Warren Buffett's Valentine's Day surprise for investors
RE
02/16WARREN BUFFETT : Warren Buffett's Valentine's Day surprise for investors
RE
02/16BACKSTORY : Warren Buffett's Valentine's Day surprise for investors
RE
02/15Cisco Systems and Teva jump while NetApp slumps
AQ
02/15TEVA PHARMACEUTICAL INDUSTRIES : closing Netanya plant, laying off 220
AQ
02/15TEVA PHARMACEUTICAL INDUSTRIES : Reports 2017 Full Year and Fourth Quarter Finan..
AQ
02/15Teva Spikes on Berkshire Stake
AQ
02/15Teva jumps on Berkshire Hathaway investment
AQ
More news
News from SeekingAlpha
04:33aTracking John Paulson's Paulson & Company Portfolio - Q4 2017 Update 
02/19Warren Buffett's Berkshire Claims $358 Million Investment In Teva, But That D.. 
02/19VALEANT : Generic Syprine Is Finally Here 
02/19MARKET ROVER : 20 High-Yield Bonds Selling Off, These 3 Are Worth Considering 
02/19TEVA : Berkshire Is Barking Up The Wrong Tree 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,05x
Capi. / Sales 2019 1,06x
Capitalization 20 599 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 18,5 $
Spread / Average Target -9,9%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED15.92%20 599
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359